Treatment of human immunodeficiency virus infection with hydroxyurea: Virologic and clinical evaluation

Journal of Infectious Diseases

Volumn 174, Issue 1, 1996, Pages 204-209

  Giacca, Mauro ^a   Zanussi, Stefania ^b   Comar, Manola ^b   Simonelli, Cecilia ^b   Vaccher, Emanuela ^b   De Paoli, Paolo ^b   Tirelli, Umberto ^b  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; HYDROXYUREA; PENTAMIDINE;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CONTROL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RNA TRANSCRIPTION; VIREMIA;

EID: 0030055872     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.1.204     Document Type: Article

References (15)

1. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 1994;266:801-5.
2. Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem 1988;57:349-74.
3. Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8.
4. Bianchi V, Borella S, Calderazzo F, Ferraro P, Chieco-Bianchi L, Reichard P. Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci USA 1994;91:8403-7.
5. Bianchi V, Pontis E, Reichard P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 1986;261:16037-42.
6. Gao WY, Johns DG, Chokekijchai S, Mitsuya H. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 1995;92:8333-7.
7. Meyerhans A, Vartanian JP, Hultgren C, et al. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 1994;68:535-40.
8. Bagnarelli P, Menzo S, Valenza A, et al. Molecular profile of human immunodeficiency virus infection in asymptomatic subjects and AIDS patients. J Virol 1992;66:7328-35.
9. Comar M, Marzio G, D'Agaro P, Giacca M. Quantitative dynamics of HIV-1 expression. AIDS Res Hum Retroviruses 1995;12:117-26.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
11. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
13. Giacca M, Borella S, Calderazzo F, et al. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3′ azido-3′ deoxythymidine on HIV-1 infection in vitro. AIDS Res Hum Retroviruses 1996 (in press).
14. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Synergistic antihuman immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994;91:11017-21.
15. Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr 1995;10:36-40.